Pharmacogenomics in Antithrombotic Therapy

Pharmacogenomics is increasingly important in personalizing antithrombotic therapy for patients at risk of thromboembolic events. By understanding how genetic variations influence drug metabolism and response, healthcare providers can optimize antiplatelet and anticoagulant treatments to maximize efficacy and minimize adverse effects. Variants in genes such as CYP2C19 and VKORC1 significantly affect patients' responses to medications like clopidogrel and warfarin. Implementing pharmacogenomic testing in clinical practice enables tailored treatment strategies, enhancing patient safety and outcomes. As pharmacogenomics continues to evolve, it will play a crucial role in personalized cardiovascular care.

    Related Conference of Pharmacogenomics in Antithrombotic Therapy

    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    June 15-16, 2026

    7th European Summit on Cardiology Research

    Zurich, Switzerland
    July 27-28, 2026

    12th International Heart Conference

    Dubai, UAE
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France
    August 17-18, 2026

    4th International Conference on World Heart Care

    Toronto, Canada
    August 24-25, 2026

    15th World Heart Congress

    London, UK
    August 27-28, 2026

    40th European Cardiology Conference

    Berlin, Germany
    November 09-10, 2026

    7th Annual Summit on Cardiology and Heart Diseases

    Paris, France
    November 16-17, 2026

    8th World Heart Congress

    Tokyo, Japan
    November 23-24, 2026

    40th World Congress on Heart Diseases

    Toronto, Canada
    November 25-26, 2026

    33rd World Heartcare Summit

    Paris, France
    March 18-19, 2027

    16th World Heart Congress

    Paris, France

    Pharmacogenomics in Antithrombotic Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in